A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
[Phase I] The main objective of this study is to evaluate the safety, tolerability and
determine the Recommended Dose (RD) of HM781-36B(Poziotinib)combined with Paclitaxel and
Trastuzumab
[Phase II] The main objective of this study is to evaluate anticancer activity through
determination of response rate of HM781-36B(Poziotinib)combined with Paclitaxel and
Trastuzumab in patients with HER-2 positive advanced gastric cancer